News

Lawing to Present on Rare Kidney Cancer at AACR Conference

Michael B. Lawing, Director of Outreach, KCCure has been selected to participate in the Scientist <-> Survivor Program at the 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Nov. 2-5, 2018 in New Orleans, LA. The conference will address all levels of basic, population, clinical, and transdisciplinary research related to cancer and will bring together physicians, scientists, health professionals, and health care leaders working in a variety of disciplines to discuss the latest findings in their fields. Patient Advocates attending the meeting will communicate to scientists the key issues, questions, and concerns of the survivor and patient advocacy communities; and network with scientists and fellow advocates fr...

Letter to Kidney Cancer Journal and Response – Regarding Checkpoint Inhibitors in Non-Clear Cell RCC

Attached is a letter to the editor of the Kidney Cancer Journal and editorial response regarding the use of checkpoint inhibitors in non-clear cell RCC. We’re grateful to the editors of the journal for graciously providing this update for patients with rare types of kidney cancer. KCJ letter

KCCure urges Congress and CMS to Reconsider Misguided Medicare Changes

KCCure joins 239 advocacy organizations asking Congress and CMS to reconsider changes allowing Medicare Advantage plans to implement a new policy that could negatively impact Medicare patients with kidney cancer.

Deadline Extension for Federal Kidney Cancer Research Program

This is to notify the research community of the recently extended deadline for the Fiscal Year 2018 (FY18) funding opportunities for the Department of Defense (DOD) Kidney Cancer Research Program (KCRP) being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).  

11th Annual Dana Farber/Harvard Cancer Center Kidney Cancer Symposium

On September 7th, the Harvard Medical Research Centers including Dana Farber, Beth Isreal, Brigham & Women's will once again hold their annual Kidney Cancer Symposium at the Newton Massachessetts Marriott. The Symposium is an all-day in-person and virtual event beginning at 8:00 a.m. and concluding at 3:30 pm. 

We Hit our Goal! $50,000 in new Research Funding for Kidney Cancer

KCCure hits goal of raising $50,000 in new kidney cancer research funding. Learn more about our Kidney Cancer Research Grant Program and our mission for find a cure for kidney cancer.

Joe Paterniti – In Memoriam

KCCure tribute to Joe Paterniti (1969-2017) a dedicated father and husband who lost his life to kidney cancer.

KCCure Urges EMA to approve Opdivo/Yervoy for European Kidney Cancer Patients

July 30, 2018 Washington, DC, – The Kidney Cancer Research Alliance(KCCure) responded to the Committee for Medicinal Products for Human Use (CHMP) recommendation against approval by the European Medicines Agency (EMA) of ipilimumab (Yervoy) combined with nivolumab (Opdivo) for the first line treatment of high and intermediate risk metastatic renal cell carcinoma (kidney cancer). The question of single-agent versus combination therapy is relevant in kidney cancer today and we agree with CHMP that additional data showing the superiority of adding ipilimumab to nivolumab would benefit the field and broaden our understanding of how these agents work in kidney cancer. However, we don’t believe this question alone is sufficient enough to justify denying kidney cancer patients access to a treatme...

What is No Tie July?

When it comes to kidney cancer, a tie isn’t good enough. We need a win. Join our month-long fundraising effort, No Tie July, and help us raise one year of life-saving research funding in just one month.

World Kidney Cancer Q&A Day – June 21st

As members of the International Kidney Cancer Coalition (IKCC), KCCure is a proud partner and participant of the second-annual World Kidney Cancer Q&A Day.

Report from ASCO – CARMENA Trial

KCCure recently attended ASCO - the world's largest cancer research conference. Learn more below on why everyone in the kidney cancer world is talking about CARMENA.

Help Share the Patient Perspective at ASCO

During ASCO, new data was presented from the “CARMENA” trial showing that overall survival for metastatic patients was not improved by performing a nephrectomy (or removing the primary tumor).  This is a controversial question and one that is being debated by many physicians.  We want to include the patient voice in that debate.  Please take a few minutes to fill out this brief survey to help us sharing the patient perspective at ASCO.  As always, your personal data will not be sharing with anyone.  Thank you for taking part!    

  • 1
  • 2
  • 6

Lost Password

Register

Subscribe for updates!